Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $430,749.44 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 30,593 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44. Following the sale, the insider directly owned 291,374 shares in the company, valued at approximately $4,102,545.92. The trade was a 9.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Francis Lo also recently made the following trade(s):

• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.09, for a total value of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total value of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.50, for a total value of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total value of $1,773,267.30.

Adaptive Biotechnologies Trading Up 5.8%

Shares of ADPT stock opened at $13.17 on Monday. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. The business’s 50-day moving average price is $16.55 and its 200-day moving average price is $15.89. Adaptive Biotechnologies Corporation has a 12 month low of $6.68 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s revenue was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. On average, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors have recently modified their holdings of the company. Ameriprise Financial Inc. increased its position in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at $65,942,000. Geode Capital Management LLC boosted its position in Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after acquiring an additional 110,825 shares during the last quarter. Finally, State Street Corp boosted its position in Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares during the last quarter. 99.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ADPT shares. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Guggenheim increased their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Morgan Stanley started coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.